Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 2
2006 1
2008 1
2009 2
2011 2
2016 1
2017 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Epigenetics in cancer: targeting chromatin modifications.
Ellis L, Atadja PW, Johnstone RW. Ellis L, et al. Among authors: atadja pw. Mol Cancer Ther. 2009 Jun;8(6):1409-20. doi: 10.1158/1535-7163.MCT-08-0860. Epub 2009 Jun 9. Mol Cancer Ther. 2009. PMID: 19509247 Free article. Review.
HDAC inhibitors and cancer therapy.
Atadja PW. Atadja PW. Prog Drug Res. 2011;67:175-95. doi: 10.1007/978-3-7643-8989-5_9. Prog Drug Res. 2011. PMID: 21141730 Review.
HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors.
Medon M, Vidacs E, Vervoort SJ, Li J, Jenkins MR, Ramsbottom KM, Trapani JA, Smyth MJ, Darcy PK, Atadja PW, Henderson MA, Johnstone RW, Haynes NM. Medon M, et al. Among authors: atadja pw. Cancer Res. 2017 May 15;77(10):2594-2606. doi: 10.1158/0008-5472.CAN-16-2247. Epub 2017 Mar 1. Cancer Res. 2017. PMID: 28249907 Free article.
Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.
Whitehead L, Dobler MR, Radetich B, Zhu Y, Atadja PW, Claiborne T, Grob JE, McRiner A, Pancost MR, Patnaik A, Shao W, Shultz M, Tichkule R, Tommasi RA, Vash B, Wang P, Stams T. Whitehead L, et al. Among authors: atadja pw. Bioorg Med Chem. 2011 Aug 1;19(15):4626-34. doi: 10.1016/j.bmc.2011.06.030. Epub 2011 Jun 15. Bioorg Med Chem. 2011. PMID: 21723733